Sacramento, Calif.-based Sutter Health has joined forces with biopharmaceutical company AstraZeneca to develop a research and innovation collaboration focused on personalized care for cardiometabolic patients.
Cardiometabolic care focuses on treating and managing diseases including diabetes, hypertension and high cholesterol in tandem with the common health complications associated with those conditions, such as heart attack, stroke, blindness and death.
Sutter Health and AstraZeneca's three-year partnership seeks to design, prototype and pilot innovative approaches to personalize care by improving access to EHR data, testing new care models and piloting new technologies.
"We have unique opportunities today to dramatically improve the patient experience and outcomes through the novel use of new technologies and the application of advanced ways of using data," said Walter "Buzz" Stewart, PhD, chief research officer for Sutter Health. "Innovation through the use of digital health solutions can and should give patients more control and ways to improve health and to work more closely with their providers to live healthier and more productive lives."
More articles on health IT:
Why Beth Israel Deaconess observes 'email-free Fridays'
Cleveland Clinic, Mayo Clinic to share analytics, algorithms on Apervita
'Digital Doctor' author Dr. Robert Wachter defends Epic's business model, product